The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•8 April 2026•

1 min read

Plus Therapeutics Secures AMA Billing Code for CNSide; Stock Dips 4.8%

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Plus Therapeutics' CNSide diagnostic system secured a dedicated AMA billing code (0640U).

2The new billing code will become effective on July 1, 2026, streamlining reimbursement processes.

3The company's stock declined by 4.80% despite the announcement of this operational milestone.

Version History

1 additional source confirmed this story

Plus Therapeutics (PSTV) announced it has secured a dedicated billing code from the American Medical Association (AMA) for its CNSide diagnostic platform. The new code, 0640U, is designed to streamline the reimbursement process for healthcare providers using the system to detect tumor cells in cerebrospinal fluid. This operational milestone is expected to enhance the company's commercial infrastructure and increase market penetration within the CNS oncology sector. However, the billing code is not scheduled to become effective until July 1, 2026, creating a significant lead time before its full impact is realized. Despite the positive long-term implications for commercial scaling, the company's stock experienced a decline of 4.80% following the announcement. Investors appear to be weighing the delayed implementation against the immediate operational progress in the biotech firm's diagnostic portfolio.